We are 2-ethylbutyl ((S)-(perfluorophenoxy)(phenoxy)phosphoryl)-L-alaninate CAS:1911578-98-7 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests
| Items of Analysis | Standard of Analysis | Test Results |
| Appearance | White or almost white powder | Conform |
| Assay(HPLC) | ＞99.0% | 99.68% |
| Moisture | ≤0.5% | 0.14% |
| Loss on drying | ≤0.5% | 0.05% |
| Residue on ignition | ≤0.10% | 0.056% |
| Enantiomeric | DR ≤0.10% | 0.0060% |
| Diastereomer | DS ≤0.1% | ND |
| LR ＜0.2% | ND | |
| Conclusion | Conforms to Factory Standard | |
Related News: However, in the long run, as the bulk API market continues to fall, more and more companies will transition to specialty API companies, and competition will intensify in the future.4-(1-naphthalenyl)-N-(1,2,3,4-tetrahydro-5-methoxy-1-naphthalenyl)-1-piperazineacetamide However, in the long run, as the bulk API market continues to fall, more and more companies will transition to specialty API companies, and competition will intensify in the future.2-Chloro-4,5-difluorobenzaldehyde CAS:165047-23-4 The Company’s immuno-regulatory product candidates include ProTmune, a pharmacologically modulated, donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease, and a myeloid-derived suppressor cell immunotherapy for promoting immune tolerance in patients with immune disorders. Fate Therapeutics is headquartered in San Diego, CA.(1S,4S)-1,4-dimethyl-1,2-dihydro-6H-pyrazino[2,1-b]quinazoline-3,6(4H)-dione The Company’s immuno-regulatory product candidates include ProTmune, a pharmacologically modulated, donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease, and a myeloid-derived suppressor cell immunotherapy for promoting immune tolerance in patients with immune disorders. Fate Therapeutics is headquartered in San Diego, CA.The Company’s immuno-regulatory product candidates include ProTmune, a pharmacologically modulated, donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease, and a myeloid-derived suppressor cell immunotherapy for promoting immune tolerance in patients with immune disorders. Fate Therapeutics is headquartered in San Diego, CA.
| Product Name | |
|---|---|
| Ethanethioic acid S-ethyl ester | View Details |
| 3,4-Diaminotoluene | View Details |
| 4,4′-Dibromotriphenylamine | View Details |